Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder Post published:March 14, 2024 Post category:Analysis/News/Pα+
Cybin Scores Breakthrough Therapy Designation for Deuterated Psilocybin Analog in MDD, Shares 4-Month Data Post published:March 13, 2024 Post category:Analysis/News/Pα+
FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder; Company Provides 12-Week Data and Fleshes Out Phase 3 Program Plans Post published:March 7, 2024 Post category:Analysis/News/Pα+
Prominent At-Home Ketamine Co. Founder, Juan Pablo Cappello, Sounds Alarm, Withdraws Support for the Practice Post published:March 4, 2024 Post category:Analysis/News/Pα+
Ibogaine Advocates Seek Ohio Opioid Settlement Funds Following Failure in Kentucky Post published:February 23, 2024 Post category:Analysis/News
Pα+: Day 2 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA Post published:February 16, 2024 Post category:Analysis/Pα+
Pα+: Day 1 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA Post published:February 14, 2024 Post category:Analysis/Pα+
The Interdisciplinary Annotated Psychedelic Research Bibliography of 2023 Post published:February 9, 2024 Post category:2023 Year in Review/Analysis
The Psychedelic Drug Development Pipeline: Bullseye Chart Year-End 2023 Post published:February 6, 2024 Post category:2023 Year in Review/Analysis
Psychedelic Policy Reform & Legal Markets in 2023 Post published:January 30, 2024 Post category:2023 Year in Review/Analysis